Sexually Transmitted Infections

Try your hand at these 5 questions on the latest US CDC STI data.

From staff training to scheduling flexibility, a primary care physician shares practical insights on integrating long-acting injectable PrEP into routine care.

Long-acting HIV prevention options simplify adherence, reduce stigma, and empower individuals to maintain their health without daily reminders.

Injection anxiety and concerns about side effects are common. A primary care physician outlines practical counseling strategies, expectation-setting, and interventions that improve patient comfort and confidence.

Real-world patient cases illustrating how pill burden, privacy, and individual preferences influence PrEP selection and adherence.

Primary care physician Kevin Hatfield, MD, discusses how the switch can increase patient touchpoints, free cognitive burden, and strengthen long-term engagement between patients and PCPs.

Gilead's ARTISTRY-2 trial shows a promising single-tablet HIV treatment regimen is noninferior to standard therapy, expanding options for virologically suppressed adults.

Zolifodacin is a single-dose oral treatment option for uncomplicated urogenital gonorrhea and one of the first new classes of drugs for the disease in 20 years.

Gepotidacin becomes the first new oral antibiotic for gonorrhea in over 30 years, offering hope for effective treatment options.

Merck reveals promising phase 3 results for DOR/ISL, showing minimal impact on weight and lipids in adults with suppressed HIV-1.

Your daily dose of the clinical news you may have missed.

New data show more than one-third of US adults are unaware of HPV or the HPV vaccine, with gaps greatest in the Midwest and South, where HPV-related cancers are most common.

FDA accepts priority review of gepotidacin for uncomplicated urogenital gonorrhea, with phase 3 data showing non-inferiority to standard injectable therapy.

New findings showcase the transformative impact of long-acting injectable therapies for effective HIV treatment and prevention.

Your daily dose of the clinical news you may have missed.

Data from the EAGLE-1 study found gepotidacin to be noninferior to ceftriaxone plus azithromycin for treating uncomplicated urogenital gonorrhea.

Your daily dose of the clinical news you may have missed.

The Women’s Sexual Health Test (Visby Medical) delivers results in approximately 30 minutes using a vaginal swab.

New research shows that treating both men and women with topical and oral antibiotics lowers the odds of bacterial vaginosis recurrence by more than half.

The FDA granted fast track designation to Sanofi’s chlamydia vaccine candidate today, aiming to prevent infections and address an unmet public health need.

CROI 2025: Researchers reported that a universal syphilis screening program identified more cases than programs targeting specific patient populations.

These test panels allow clinicians to diagnose multiple STIs from a single specimen, with results available in about 20 minutes.

Your daily dose of the clinical news you may have missed.

Comments on the draft recommendation can be submitted through December 23, 2024.

The CDC just released its annual STD surveillance report. Are you caught up on the latest trends? Try your hand at these 7 questions to find out.